Opportunity Information: Apply for PA 10 269
Apply for PA 10 269
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Neuroscience Research on Drug Abuse (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Aug 20, 2010 and posted on Aug 20, 2010.
- Applicants must submit their applications by Sep 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Independent school districts State governments City or township governments Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Small businesses Special district governments Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Neuroscience Research on Drug Abuse (R21) (Funding Opportunity Number PA-10-269) is a National Institute on Drug Abuse (NIDA), NIH funding opportunity designed to support early-stage, high-impact neuroscience research that advances understanding of drug use, dependence, and addiction. The focus is on the underlying processes and mechanisms of drug abuse and addiction, and projects can be carried out in a wide range of research settings, including model systems, animal studies, and human research. The emphasis is on generating new ideas and preliminary evidence that can open up promising directions in biomedical, behavioral, or clinical science related to substance use and addiction.
The award mechanism is the NIH Exploratory/Developmental Grant (R21), which is specifically intended for exploratory and developmental work at the earlier, more conceptual stages of a research line. In practice, this means NIDA is looking for projects that may be innovative, untested, or higher-risk than a typical hypothesis-driven study, but that have a realistic chance of producing a major advance. Examples of the kinds of outcomes this mechanism is meant to enable include breakthrough findings in an emerging area, the creation of novel techniques or methodologies, development of new research agents or tools, establishment of new models, or the first demonstration of a new application that could reshape future addiction research.
This FOA is part of a coordinated set of announcements with the same scientific scope offered under different NIH grant mechanisms. Alongside this R21 opportunity, applicants with more mature projects can consider the parallel R01 announcement (PA-10-268), while smaller, more limited-scope feasibility or pilot efforts may align with the R03 announcement (PA-10-270). The R21, in contrast, sits in the middle by supporting innovative concept development and early validation work that is not yet ready for a full-scale R01 but goes beyond what an R03 typically supports.
In terms of project length and budget, the R21 under this FOA is capped at a two-year project period. Direct costs are limited to a total of $275,000 across the two years, with an additional constraint that no single year may exceed $200,000 in direct costs. Because proposed studies can vary widely in approach and resource needs, NIDA notes that actual award sizes, durations (within the two-year limit), and the number of awards made depend on the quality, cost, and scope of the applications received, as well as available funds.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (other than small businesses as well as small businesses), state and local governments (including county, city/township, special district, and independent school districts), Native American tribal governments and organizations, public housing authorities/Indian housing authorities, and U.S. territories or possessions. The FOA also explicitly includes eligibility for groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and foreign (non-U.S.) entities, among others. Cost sharing or matching is not required.
Administratively, the opportunity falls under the NIH and is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs). The announcement was posted on August 20, 2010, with an original and current closing date of September 7, 2013, and an archive date of October 8, 2013, indicating it is no longer active as a current competition but remains available as a historical reference. The public listing includes an award ceiling of $200,000, which aligns with the stated per-year direct cost cap, while the overall two-year direct cost limit remains $275,000. The full announcement was available via the NIH Grants Guide (http://grants.nih.gov/grants/guide/pa-files/PA-10-269.html), and NIH’s Office of Extramural Research webmaster contact is provided for access or link issues.
Frequently Asked Questions (FAQs): Neuroscience Research on Drug Abuse (R21) - PA-10-269
What is the Neuroscience Research on Drug Abuse (R21) opportunity (PA-10-269)?
PA-10-269 is a National Institute on Drug Abuse (NIDA), NIH funding opportunity that supports early-stage, high-impact neuroscience research focused on advancing understanding of drug use, dependence, and addiction. The emphasis is on underlying processes and mechanisms of drug abuse and addiction.
Which NIH institute sponsors this funding opportunity?
This opportunity is sponsored by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).
What grant mechanism does PA-10-269 use?
The award mechanism is the NIH Exploratory/Developmental Grant (R21), intended for exploratory and developmental research at earlier, more conceptual stages.
What types of research does this FOA aim to support?
The FOA targets neuroscience research that advances understanding of drug use, dependence, and addiction, with a focus on processes and mechanisms underlying drug abuse and addiction. Projects are intended to generate new ideas and preliminary evidence that could open promising directions in biomedical, behavioral, or clinical substance use and addiction research.
What kinds of research settings are allowed for proposed projects?
Projects may be carried out in a wide range of research settings, including model systems, animal studies, and human research.
Is this FOA intended for mature, fully developed projects?
No. The R21 mechanism is specifically intended for exploratory and developmental work that is earlier-stage and more conceptual. NIDA describes these projects as potentially innovative, untested, or higher-risk than typical hypothesis-driven studies, while still having a realistic chance of producing a major advance.
What types of outcomes is the R21 mechanism meant to enable under this FOA?
Examples of outcomes described for this mechanism include breakthrough findings in an emerging area, creation of novel techniques or methodologies, development of new research agents or tools, establishment of new models, or an initial demonstration of a new application that could shape future addiction research.
How long can an R21 project last under PA-10-269?
The project period is capped at two years.
What is the budget limit for this R21 opportunity?
Direct costs are limited to a total of $275,000 across the two-year project period, with an additional constraint that no single year may exceed $200,000 in direct costs.
Why does the listing show an award ceiling of $200,000?
The public listing includes an award ceiling of $200,000, which aligns with the stated per-year direct cost cap. Separately, the FOA also states the overall two-year direct cost limit of $275,000.
Are cost sharing or matching funds required?
No. The FOA states that cost sharing or matching is not required.
How are award sizes and the number of awards determined?
NIDA notes that actual award sizes, durations (within the two-year limit), and the number of awards depend on the quality, cost, and scope of applications received, as well as available funds.
Is PA-10-269 part of a larger set of related NIH announcements?
Yes. This FOA is part of a coordinated set of announcements with the same scientific scope offered under different NIH grant mechanisms.
What are the related announcements, and how do they differ?
Alongside this R21 opportunity (PA-10-269), there is a parallel R01 announcement for more mature projects (PA-10-268) and an R03 announcement for smaller, limited-scope feasibility or pilot efforts (PA-10-270). The R21 is positioned in the middle: it supports innovative concept development and early validation work that is not yet ready for a full-scale R01 but generally goes beyond what an R03 supports.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic and non-domestic organizations. Examples listed include public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (including small businesses); state and local governments (including county, city/township, special district, and independent school districts); Native American tribal governments and organizations; public housing authorities/Indian housing authorities; and U.S. territories or possessions.
Are foreign (non-U.S.) organizations eligible?
Yes. The FOA explicitly includes eligibility for foreign (non-U.S.) entities among the eligible applicants.
Does the FOA mention specific institution types as eligible (such as HBCUs or HSIs)?
Yes. The FOA explicitly includes a range of institution types and groups, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and others.
What is the CFDA number associated with this opportunity?
The opportunity is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
When was PA-10-269 posted?
The announcement was posted on August 20, 2010.
Is this funding opportunity still open?
No. The original and current closing date is listed as September 7, 2013, and the archive date is October 8, 2013, indicating it is no longer active as a current competition and is available as a historical reference.
Where could applicants find the full announcement?
The full announcement was available via the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PA-10-269.html.
Who is listed as a contact for access or link issues?
The listing notes that NIH's Office of Extramural Research webmaster contact is provided for access or link issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Neuroscience Research on Drug Abuse (R03)
Previous opportunity: Neuroscience Research on Drug Abuse (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 269
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 269) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neuroscience Research on Drug Abuse (R03) Apply for PA 10 270 Funding Number: PA 10 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R21/R33) Apply for PAS 10 274 Funding Number: PAS 10 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR R41 Apply for RFA DA 11 004 Funding Number: RFA DA 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Developing and Improving Institutional Animal Resources (G20) Apply for RFA RR 10 011 Funding Number: RFA RR 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) Apply for RFA CA 10 013 Funding Number: RFA CA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Assay Development for High Throughput Screening for Nicotinic Receptor Subunits (R21) Apply for RFA DA 11 007 Funding Number: RFA DA 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 10 283 Funding Number: PAR 10 283 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR U43/U44) Apply for PAR 10 286 Funding Number: PAR 10 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| 2011 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 11 002 Funding Number: RFA DA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the 2011 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 10 287 Funding Number: PAR 10 287 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Resource Related Research Projects for Development of Animal Models and Related Materials (R24) Apply for PAR 10 289 Funding Number: PAR 10 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Malignancies in the Context of HIV/AIDS (R01) Apply for PA 10 290 Funding Number: PA 10 290 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Malignancies in the Context of HIV/AIDS (R21) Apply for PA 10 291 Funding Number: PA 10 291 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Tumor Microenvironment Network (TMEN) (U54) Apply for RFA CA 10 021 Funding Number: RFA CA 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Animal and Biological Material Resource Centers (P40) Apply for PAR 11 001 Funding Number: PAR 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 11 005 Funding Number: PAR 11 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (U54) Apply for RFA CA 11 001 Funding Number: RFA CA 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine (K23) Apply for PA 11 009 Funding Number: PA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PA 11 008 Funding Number: PA 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PA 11 006 Funding Number: PA 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 269", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.